Get the Stockscreener App
0.5108
27.19%
0.1092
After Hours:
.48
-0.0308
-6.03%
Neurosense Therapeutics Ltd stock is traded at $0.5108, with a volume of 4.14M.
It is up +27.19% in the last 24 hours and down -1.75% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$0.4016
Open:
$0.4
24h Volume:
4.14M
Relative Volume:
18.89
Market Cap:
$19.29M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-0.8744
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
+21.50%
1M Performance:
-1.75%
6M Performance:
-42.54%
1Y Performance:
-53.56%
1-Day Range:
$0.36
$0.5257
1-Week Range:
$0.36
$0.5257
52-Week Range:
$0.25
$1.98
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.5108 | 13.23M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com
NeuroSense Issues CEO Letter to Shareholders - Nasdaq
NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans - Bitget
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et
Global Neurodegenerative Disease Market is Expected to - GlobeNewswire
NRSN Q2 2025 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Pipeline AdvancesEarnings Revision Downgrade - vinanet.vn
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
NeuroSense Therapeutics (NRSN) Jumps 11.35% to $0.52, Nears Key Resistance at $0.55Revenue Growth Stocks - dars.gov.et
NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split - TipRanks
NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock Titan
NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan - Stock Titan
NeuroSense Therapeutics (NRSN) Plunges 14% – Testing Critical Support at $0.46Sentiment Shift - vinanet.vn
Neurosense Therapeutics is a buy, this analyst says - Cantech Letter
Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView
Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z - TradingView
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.500|Chg%:-0.003 - TradingKey
TradingKey - TradingKey
NeuroSense Therapeutics (NRSN) Gains 3.08% as Stock Tests Key Resistance at $0.70Upthrust Pattern - vinanet.vn
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks
NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Fails to Soothe ShareholdersHealthcare Earnings Report - vinanet.vn
NeuroSense Therapeutics (NRSN) Faces Headwinds: Stock Retreats 5.6% to $0.69 Amid Sector PressureMarket Profile - vinanet.vn
NeuroSense Therapeutics (NRSN) Slips 2.6% as Stock Tests Key Support at $0.65Cumulative Volume - vinanet.vn
NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66Calendar Spread Trade - dars.gov.et
NeuroSense Therapeutics (NRSN) Edges Higher as Key Support HoldsEquity Put Call - dars.gov.et
NeuroSense Therapeutics Ltd. (NRSN) Latest Stock News & Headlines - Yahoo Finance
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - Nasdaq
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings - TradingView
NeuroSense bolsters case for multi-target Alzheimer’s strategy - Longevity.Technology
NRSN Q2 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineBasic EPS Analysis - dars.gov.et
NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS - Bakersfield.com
NeuroSense (NRSN) Achieves Key Milestone in ALS Study - GuruFocus
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3 - TipRanks
NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint - marketscreener.com
NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3 - Stock Titan
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - Nasdaq
NeuroSense reports positive Phase 2b ALS data - grafa.com
NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease - BioSpectrum Asia
Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN) - TradingView
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurosense Therapeutics Ltd Stock (NRSN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ben-Noon Alon | Chief Executive Officer |
Jun 16 '26 |
Buy |
0.80 |
250,000 |
200,000 |
4,534,233 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):